GB201215857D0 - siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions - Google Patents

siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Info

Publication number
GB201215857D0
GB201215857D0 GBGB1215857.2A GB201215857A GB201215857D0 GB 201215857 D0 GB201215857 D0 GB 201215857D0 GB 201215857 A GB201215857 A GB 201215857A GB 201215857 D0 GB201215857 D0 GB 201215857D0
Authority
GB
United Kingdom
Prior art keywords
sirna
prevention
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1215857.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sylentis SA
Original Assignee
Sylentis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis SA filed Critical Sylentis SA
Priority to GBGB1215857.2A priority Critical patent/GB201215857D0/en
Publication of GB201215857D0 publication Critical patent/GB201215857D0/en
Priority to BR112015004469A priority patent/BR112015004469B8/pt
Priority to US14/425,459 priority patent/US9808479B2/en
Priority to PE2015000282A priority patent/PE20150619A1/es
Priority to PT13759707T priority patent/PT2893019T/pt
Priority to HRP20181079TT priority patent/HRP20181079T1/hr
Priority to ES13759707.6T priority patent/ES2685346T3/es
Priority to HUE13759707A priority patent/HUE040096T2/hu
Priority to KR1020157006165A priority patent/KR102136539B1/ko
Priority to EP13759707.6A priority patent/EP2893019B1/en
Priority to SI201331090T priority patent/SI2893019T1/sl
Priority to CN201810353730.8A priority patent/CN108354944A/zh
Priority to PCT/EP2013/068245 priority patent/WO2014037377A1/en
Priority to CA2883040A priority patent/CA2883040C/en
Priority to IN2501DEN2015 priority patent/IN2015DN02501A/en
Priority to RU2015112121A priority patent/RU2663100C2/ru
Priority to SG11201501386TA priority patent/SG11201501386TA/en
Priority to AU2013311781A priority patent/AU2013311781B2/en
Priority to PL13759707T priority patent/PL2893019T3/pl
Priority to DK13759707.6T priority patent/DK2893019T3/en
Priority to HK16100039.5A priority patent/HK1212377B/en
Priority to RS20180877A priority patent/RS57620B1/sr
Priority to JP2015530372A priority patent/JP2015529210A/ja
Priority to CN201380046215.0A priority patent/CN104640988A/zh
Priority to LTEP13759707.6T priority patent/LT2893019T/lt
Priority to MX2015002802A priority patent/MX362854B/es
Priority to IL237389A priority patent/IL237389B/en
Priority to CL2015000537A priority patent/CL2015000537A1/es
Priority to ZA2015/01494A priority patent/ZA201501494B/en
Priority to ECIEPI20159391A priority patent/ECSP15009391A/es
Priority to JP2018090693A priority patent/JP6742362B2/ja
Priority to CY181100845T priority patent/CY1121000T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GBGB1215857.2A 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions Ceased GB201215857D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB1215857.2A GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
MX2015002802A MX362854B (es) 2012-09-05 2013-09-04 Siarn y su uso en los metodos y composiciones para el tratamiento y/o prevencion de enfermedades de los ojos.
IN2501DEN2015 IN2015DN02501A (enExample) 2012-09-05 2013-09-04
RU2015112121A RU2663100C2 (ru) 2012-09-05 2013-09-04 Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
PE2015000282A PE20150619A1 (es) 2012-09-05 2013-09-04 Moleculas de siarn que interfieren con la expresion del receptor vaniloide-1 (trpv1)
PT13759707T PT2893019T (pt) 2012-09-05 2013-09-04 Siarn e sua utilização em métodos e composições para o tratamento e/ou p~venção de afeções do olho
HRP20181079TT HRP20181079T1 (hr) 2012-09-05 2013-09-04 Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja
ES13759707.6T ES2685346T3 (es) 2012-09-05 2013-09-04 ARNip y su uso en métodos y composiciones para el tratamiento y/o la prevención de afecciones oculares
HUE13759707A HUE040096T2 (hu) 2012-09-05 2013-09-04 siRNS és felhasználása eljárásokban és kompozíciókban szembajok kezelésére és/vagy megelõzésére
KR1020157006165A KR102136539B1 (ko) 2012-09-05 2013-09-04 눈 증상의 치료 및/또는 예방을 위한 방법 및 조성물에서 sirna 및 이들의 용도
AU2013311781A AU2013311781B2 (en) 2012-09-05 2013-09-04 SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
SI201331090T SI2893019T1 (sl) 2012-09-05 2013-09-04 siRNA IN NJENA UPORABA V POSTOPKIH IN SESTAVKIH ZA ZDRAVLJENJE IN/ALI PREPREČEVANJU OBOLENJ OČI
CN201810353730.8A CN108354944A (zh) 2012-09-05 2013-09-04 siRNA及其在用于治疗和/或预防眼部病症的方法和组合物中的应用
PCT/EP2013/068245 WO2014037377A1 (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2883040A CA2883040C (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
BR112015004469A BR112015004469B8 (pt) 2012-09-05 2013-09-04 Kit medicinal para administração de um sirna
SG11201501386TA SG11201501386TA (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
PL13759707T PL2893019T3 (pl) 2012-09-05 2013-09-04 siRNA i jego zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania chorobom oczu
EP13759707.6A EP2893019B1 (en) 2012-09-05 2013-09-04 Sirna and its use in methods and compositions for the treatment and/or prevention of eye conditions
US14/425,459 US9808479B2 (en) 2012-09-05 2013-09-04 SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
DK13759707.6T DK2893019T3 (en) 2012-09-05 2013-09-04 SIRNA AND ITS USE IN METHODS AND COMPOSITIONS FOR TREATMENT AND / OR PREVENTION OF EYE DISEASES
HK16100039.5A HK1212377B (en) 2012-09-05 2013-09-04 Sirna and its use in methods and compositions for the treatment and/or prevention of eye conditions
RS20180877A RS57620B1 (sr) 2012-09-05 2013-09-04 Sirnk i njena primena u metodama i kompozicijama za lečenje i/ili prevenciju očnih stanja
JP2015530372A JP2015529210A (ja) 2012-09-05 2013-09-04 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用
CN201380046215.0A CN104640988A (zh) 2012-09-05 2013-09-04 siRNA及其在用于治疗和/或预防眼部病症的方法和组合物中的应用
LTEP13759707.6T LT2893019T (lt) 2012-09-05 2013-09-04 Sirnr ir jos panaudojimas būduose ir kompozicijose, skirtose akių ligų gydymui ir (arba) prevencijai
IL237389A IL237389B (en) 2012-09-05 2015-02-24 Short interfering RNA and its use in methods and preparations for the treatment and/or prevention of eye diseases
CL2015000537A CL2015000537A1 (es) 2012-09-05 2015-03-04 Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
ZA2015/01494A ZA201501494B (en) 2012-09-05 2015-03-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
ECIEPI20159391A ECSP15009391A (es) 2012-09-05 2015-03-12 siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
JP2018090693A JP6742362B2 (ja) 2012-09-05 2018-05-09 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用
CY181100845T CY1121000T1 (el) 2012-09-05 2018-08-10 Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1215857.2A GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
GB201215857D0 true GB201215857D0 (en) 2012-10-24

Family

ID=47136985

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1215857.2A Ceased GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Country Status (29)

Country Link
US (1) US9808479B2 (enExample)
EP (1) EP2893019B1 (enExample)
JP (2) JP2015529210A (enExample)
KR (1) KR102136539B1 (enExample)
CN (2) CN104640988A (enExample)
AU (1) AU2013311781B2 (enExample)
BR (1) BR112015004469B8 (enExample)
CA (1) CA2883040C (enExample)
CL (1) CL2015000537A1 (enExample)
CY (1) CY1121000T1 (enExample)
DK (1) DK2893019T3 (enExample)
EC (1) ECSP15009391A (enExample)
ES (1) ES2685346T3 (enExample)
GB (1) GB201215857D0 (enExample)
HR (1) HRP20181079T1 (enExample)
HU (1) HUE040096T2 (enExample)
IL (1) IL237389B (enExample)
IN (1) IN2015DN02501A (enExample)
LT (1) LT2893019T (enExample)
MX (1) MX362854B (enExample)
PE (1) PE20150619A1 (enExample)
PL (1) PL2893019T3 (enExample)
PT (1) PT2893019T (enExample)
RS (1) RS57620B1 (enExample)
RU (1) RU2663100C2 (enExample)
SG (1) SG11201501386TA (enExample)
SI (1) SI2893019T1 (enExample)
WO (1) WO2014037377A1 (enExample)
ZA (1) ZA201501494B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194751A1 (en) 2011-06-30 2013-12-30 Arrowhead Res Corp Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2017027350A2 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
AU2020222348B2 (en) 2019-02-15 2023-03-16 Bausch + Lomb Ireland Limited Methods for treating ocular surface pain
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CA3156484A1 (en) * 2019-10-04 2021-04-08 Senju Pharmaceutical Co., Ltd. PHARMACEUTICAL MEDICINAL PRODUCT CONTAINING A HETEROCYCLIDENE ACETAMIDE DERIVATIVE

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20030148987A1 (en) 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
EP1534840A4 (en) 2002-07-24 2006-01-18 Immusol Inc NEW SIRNA GENIUS LIBRARIES AND METHOD FOR THEIR MANUFACTURE AND USE
AU2003254162A1 (en) 2002-07-24 2004-02-09 Immusol Incorporated Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
BRPI0313202A8 (pt) 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
AU2003282877B9 (en) 2002-09-25 2011-05-12 University Of Massachusetts In Vivo gene silencing by chemically modified and stable siRNA
MXPA05004722A (es) 2002-11-01 2005-08-03 Univ Pennsylvania Composiciones y metodos para la inhibicion del factor inducible por hipoxia 1 alfa con acido ribonucleico corto de interferencia.
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7462602B2 (en) 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
WO2005044976A2 (en) 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
EP2314689A3 (en) * 2003-12-03 2012-12-19 Coda Therapeutics (NZ) Ltd Antisense compounds targeted to connexins and methods of use thereof
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20090247604A1 (en) 2004-02-05 2009-10-01 Intradigm Corporation RNAi Therapeutics for Treatment of Eye Neovascularization Diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
WO2005089224A2 (en) 2004-03-12 2005-09-29 Alnylam Pharmaceuticals, Inc. iRNA AGENTS TARGETING VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CN105251024A (zh) 2004-08-23 2016-01-20 西伦蒂斯私人股份公司 眼病的治疗
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
KR20080018858A (ko) 2005-03-11 2008-02-28 알콘, 인코퍼레이티드 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
BRPI0715821A2 (pt) * 2006-08-24 2013-07-23 Alcon Res Ltd inibiÇço de gremlina mediada por rnai para tratamento de condiÇÕes relacionadas À iop
WO2009023025A1 (en) 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
CN201337650Y (zh) * 2009-01-06 2009-11-04 河北科技大学 一次性药用单剂量液体容器
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Also Published As

Publication number Publication date
MX362854B (es) 2019-02-20
HUE040096T2 (hu) 2019-02-28
BR112015004469A2 (pt) 2017-08-08
ZA201501494B (en) 2016-01-27
IL237389B (en) 2019-01-31
US9808479B2 (en) 2017-11-07
BR112015004469B8 (pt) 2022-12-06
PT2893019T (pt) 2018-10-19
CN108354944A (zh) 2018-08-03
ES2685346T3 (es) 2018-10-08
SG11201501386TA (en) 2015-03-30
CY1121000T1 (el) 2019-12-11
CN104640988A (zh) 2015-05-20
US20150224131A1 (en) 2015-08-13
PE20150619A1 (es) 2015-05-11
AU2013311781A1 (en) 2015-03-12
MX2015002802A (es) 2015-05-15
KR102136539B1 (ko) 2020-07-23
HRP20181079T1 (hr) 2018-09-07
AU2013311781B2 (en) 2018-10-18
ECSP15009391A (es) 2015-12-31
IN2015DN02501A (enExample) 2015-09-11
LT2893019T (lt) 2018-08-10
HK1212377A1 (en) 2016-06-10
JP6742362B2 (ja) 2020-08-19
SI2893019T1 (sl) 2018-09-28
CA2883040A1 (en) 2014-03-13
KR20150047513A (ko) 2015-05-04
CA2883040C (en) 2023-01-17
RS57620B1 (sr) 2018-11-30
CL2015000537A1 (es) 2015-07-10
JP2015529210A (ja) 2015-10-05
RU2663100C2 (ru) 2018-08-01
RU2015112121A (ru) 2016-10-27
PL2893019T3 (pl) 2018-12-31
DK2893019T3 (en) 2018-09-03
IL237389A0 (en) 2015-04-30
BR112015004469B1 (pt) 2022-11-16
WO2014037377A1 (en) 2014-03-13
EP2893019B1 (en) 2018-05-30
EP2893019A1 (en) 2015-07-15
JP2018138596A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
ZA201402615B (en) Prevention and treatment of ocular conditions
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
IL237528A0 (en) Methods for preventing and treating preeclampsia
GB201217296D0 (en) Method of treatment and/or prevention
ZA201408055B (en) Compositions and methods for the treatment of local pain
ZA201408056B (en) Compositions and methods for the treatment of mucositis
SI2576782T1 (sl) siRNA in njena uporaba v postopkih in sestavkih za zdravljenje in/ali preprečevanje očesnih stanj
EP2869819A4 (en) COMPOSITIONS, METHODS AND / OR DEVICES FOR THE PREVENTION AND / OR TREATMENT OF OCULAR DROUGHT DISORDERS
PT2854910T (pt) Níveis de ceramida no tratamento e prevenção de infeções
HUE044216T2 (hu) Kitin vagy annak származékai parazitózisok megelõzésére és/vagy kezelésére
ZA201501494B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
IL245123A0 (en) Short interfering RNA and its use in methods and preparations for preventing the expression of the orai1 gene
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
ZA201502181B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
AU2012902937A0 (en) Composition for prevention and treatment of eye disorder
ZA201501068B (en) Methods for prevention and treatment of preeclampsia

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)